1. Brix G, Günther E, Rössler U, Endesfelder D, Kamp A, Beer A, Eiber M. Double-strand breaks in lymphocyte DNA of humans exposed to [18F]fluorodeoxyglucose and the static magnetic field in PET/MRI. EJNMMI Research 2020; 10: 43.
  2. Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, Graner FP, Kubler H, Haberkorn U, Eisenhut M, Wester HJ, Gschwend JE, Schwaiger M. Evaluation of Hybrid Ga-68-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. Journal of Nuclear Medicine 2020; 61: 248S-54S.
  3. Graeter T, Eberhardt N, Shi R, Schmidberger J, Beer AJ, Beer M, Henne-Bruns D, Hillenbrand A, Barth TFE, Grimm J, Kratzer W, Gruener B. Hepatic alveolar echinococcosis: correlation between computed tomography morphology and inflammatory activity in positron emission tomography. Sci Rep 2020; 10: 11808.
  4. Graf J, Pape UF, Jann H, Denecke T, Arsenic R, Brenner W, Pavel M, Prasad V. Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE. Eur J Nucl Med Mol Imaging 2020; 47: 881-94.
  5. Grimm J, Beck A, Nell J, Schmidberger J, Hillenbrand A, Beer AJ, Dezsenyi B, Shi R, Beer M, Kern P, Henne-Bruns D, Kratzer W, Moller P, Barth TFE, Gruener B, Graeter T. Combining Computed Tomography and Histology Leads to an Evolutionary Concept of Hepatic Alveolar Echinococcosis. Pathogens 2020; 9: 14.
  6. Gruber L, Jimenez-Franco LD, Decristoforo C, Uprimny C, Glatting G, Hohenberger P, Schoenberg SO, Reindl W, Orlandi F, Mariani M, Jaschke W, Virgolini I. MITIGATE-NeoBOMB1, a Phase I/IIa Study to Evaluate Safety, Pharmacokinetics, and Preliminary Imaging of Ga-68-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients. J Nucl Med 2020; 61: 1749-55.
  7. Harms M, Gilg A, Standker L, Beer AJ, Mayer B, Rasche V, Gruber CW, Munch J. Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands. Sci Rep 2020; 10: 16036.
  8. Kloth C, Beck A, Wittau M, Thaiss WM, Vogele D, Beer M, Schmidt SA. Rare case of a pancreatic neoplasm in an older patient. Radiologe 2020; 60: 1066-8.
  9. Merola E, Prasad V, Pascher A, Pape UF, Arsenic R, Denecke T, Fehrenbach U, Wiedenmann B, Pavel ME. Peritoneal Carcinomatosis in Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Clinical Impact and Effectiveness of the Available Therapeutic Options. Neuroendocrinology 2020; 110: 517-24.
  10. Miksch J, Bottke D, Krohn T, Thamm R, Bartkowiak D, Solbach C, Bolenz C, Beer M, Wiegel T, Beer AJ, Prasad V. Interobserver variability, detection rate, and lesion patterns of 68Ga-PSMA-11-PET/CT in early-stage biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2020; 47: 2339-47.
  11. Patt M, Solbach C, Breitkreutz F, Schulze R. Zur rechtlichen Einordnung diagnostischer Radiopharmaka in der nuklearmedizinischen Forschung mit gesunden Probanden. Nuklearmedizin 2020; 59: 394-5.
  12. Prasad V. Pathologist at the doorstep of cancer "I know your weaknesses and strength": an interview with Jean Claude Reubi. Eur J Nucl Med Mol Imaging 2020; 47: 741-3.
  13. Prasad V, Srirajaskanthan R, Toumpanakis C, Grana CM, Baldari S, Shah T, Lamarca A, Courbon F, Scheidhauer K, Baudin E, Thanh XMT, Houchard A, Dromain C, Bodei L. Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice. Eur J Nucl Med Mol Imaging 2020; 47: 2358-71.
  14. Rinscheid A, Kletting P, Eiber M, Beer AJ, Glatting G. Influence of sampling schedules on [Lu-177]Lu-PSMA dosimetry. EJNMMI Phys 2020; 7: 41.
  15. Winter G, Koch ABF, Löffler J, Jelezko F, Linden M, Li H, Abaei A, Zuo Z, Beer AJ, Rasche V. In vivo PET/MRI Imaging of the Chorioallantoic Membrane. Front Physics 2020; 8: 151.
  16. Winter G, Koch ABF, Loffler J, Linden M, Solbach C, Abaei A, Li H, Glatting G, Beer AJ, Rasche V. Multi-Modal PET and MR Imaging in the Hen's Egg Test-Chorioallantoic Membrane (HET-CAM) Model for Initial In Vivo Testing of Target-Specific Radioligands. Cancers 2020; 12(5): 1248.